

▼ After you have received medical advice for any side effects you experience, you can report side effects to Medsafe online at <https://www.medsafe.govt.nz/safety/report-a-problem.asp>. By reporting side effects, you can help provide more information on the safety of this medicine.

Patient Alert Card TEVIMBRA® (tislelizumab)

Name of TEVIMBRA® Prescriber:

Phone:

Patient Name:

Patient Phone:

Emergency Contact Name:

Emergency Contact (Phone):

For more information, consult the TEVIMBRA® Consumer Medicine Information (CMI)

BeOne Medicines NZ Unlimited,
c/o Quigg Partners,
Level 7, The Bayleys Building,
36 Brandon Street,
Wellington, 6011
New Zealand

TEVIMBRA (tislelizumab) is an unfunded Prescription Medicine - your patient will need to pay for this medicine and any health professional fees that apply. See BeOne Access Program for more information.

Date of Preparation: February 2026.
ID: 0126-TEV-PRC-036. TAPS BG5942



Important safety Information to minimize the risk of Immune-mediated adverse reactions

- ▼ If you have any questions about how TEVIMBRA® works or why this medicine has been prescribed for you, ask your doctor.
- ▼ If you experience any adverse reactions (side effects), talk to your doctor. This includes any possible side effects not listed on this card.
- ▼ Do not attempt to self-treat any symptoms without consulting a healthcare professional first.
- ▼ It is important that you **carry the Patient Card with you at all times** and show it to healthcare professionals at all medical visits (e.g., emergency healthcare professionals) to help with diagnosing and treating immune-related adverse reactions.

Look out for serious adverse reactions (side effects)

TEVIMBRA® can have serious side effects, which can sometimes become life-threatening and can lead to death. Tell your doctor immediately if you get any of these side effects during treatment with TEVIMBRA®:

- **Lungs:** Shortness of breath, chest pain, new or worsening cough.
- **Liver:** Nausea, vomiting, pain on right side of the stomach, loss of appetite, yellowing of eyes and skin, bleeding or bruising more easily than normal, dark colored urine.
- **Bowel:** Diarrhea or more bowel movements than normal, black, tarry, sticky stools, blood or mucus in stools, severe pain or tenderness in the stomach, nausea, vomiting.
- **Kidney and bladder:** Changes in the amount and color of the urine.
- **Skin:** Rash, itching, skin blistering or ulcers in the mouth or on other moist surfaces of nose, throat, genital areas, dry skin.
- **Hormone-producing glands (especially the adrenal, pituitary, or thyroid glands):** Fast heart rate, sweating, extreme tiredness, weight changes, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away, or unusual headaches, vision changes, changes in mood or behavior, such as decreased sex drive, irritability or forgetfulness, deeper voice.
- **Type 1 diabetes mellitus:** Feeling more hungry or thirsty than normal, passing urine more often than normal, fruity smelling breath.
- **Muscles:** Muscle pain and stiffness.
- **Heart:** Chest pain, rapid or abnormal heartbeat, shortness of breath at rest or during activity, fluid build-up with swelling of the legs, ankles and feet.
- **Others:** Fever, fatigue, difficulty walking, confusion, drowsiness, stiff neck, seizures, pain, weakness, numbness, tingling, swollen lymph nodes.

Important Information for Health Care Providers

- ▼ This patient is being treated with TEVIMBRA® (tislelizumab), which can cause immune-mediated adverse reactions that may appear at any time during treatment or even after treatment. Assess patients for signs and symptoms of immune-mediated adverse reactions. Early diagnosis and appropriate management are essential to minimize any consequences of immune-mediated adverse reactions.
- ▼ For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm the etiology and exclude other causes. Depending on the type and severity of immune-mediated adverse reactions, consider withholding tislelizumab and administering corticosteroids. **Specific guidelines for managing immune-mediated adverse reactions are available in the TEVIMBRA® Product Information.**
- ▼ All suspected adverse drug reactions (ADRs) can also be reported to local regulatory authorities.